Jack Dixon will become dean for scientific affairs and health sciences at the University of California, San Diego, in February, following George Palade, who retired about a year ago. Dixon currently directs the life sciences institute at the University of Michigan. In California, he will also hold faculty appointments as professor of pharmacology and of cellular and molecular medicine. Dixon is known for his work on signal transduction, especially phosphatases and their role in cancer as well as in the cellular response to bacterial toxins. He has a BA from UCLA and a PhD from UC Santa Barbara, and conducted postdoctoral research at UCSD.
Julia Ronde has joined Oxford GlycoSciences as head of human resources. Most recently, she was vice president for human resources at Parexel International.
Peter Zagorin has become vice president for marketing at OGS, joining the company from the US pharmaceutical division of Bayer, where he was deputy director for anti-infective marketing. Besides product marketing, he will be responsible for corporate communications.
James Yee has been appointed head of development at Celera Genomics. He will be responsible for building the development organization at Celera South San Francisco and for leading therapeutic development and clinical trials at Celera. Yee joins the company from Roche Bioscience, where he was vice president for clinical and preclinical research for the inflammatory and viral diseases unit. Prior to that, he held a variety of research and development positions at Syntex and Roche Pharmaceuticals.
Robert Neumeister Jr. has left Myriad Proteomics, where he was CFO, to become executive vice president and CFO of directory company Dex Media East. He holds an MBA from the University of Virginia’s Colgate Darden Graduate School of Business and a bachelor’s degree in Economics and English from Vanderbilt University.